FDA Approvals, Dividends, Promoting Diversity, Result Publications and Acquisitions - Research Report on Gilead, St. Jude

    FDA Approvals, Dividends, Promoting Diversity, Result Publications and
      Acquisitions - Research Report on Gilead, St. Jude Medical, Cigna,
                         Pharmacyclics, and LifePoint

PR Newswire

NEW YORK, December 17, 2013

NEW YORK, December 17, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Gilead
Sciences Inc. (NASDAQ: GILD), St. Jude Medical Inc. (NYSE: STJ), Cigna Corp.
(NYSE: CI), Pharmacyclics Inc. (NASDAQ: PCYC), and LifePoint Hospitals Inc.
(NASDAQ: LPNT). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Gilead Sciences Inc. Research Report

On December 6, 2013, Gilead Sciences Inc. (Gilead) announced the US Food and
Drug Administration (FDA) approval of Sovaldi for the treatment of chronic
hepatitis C (CHC) infection as a component of a combination antiviral
treatment regimen. Gilead reported that Sovaldi's efficacy has been
established in subjects with hepatitis C virus (HCV) genotypes 1, 2, 3 or 4
infection, including those with hepatocellular carcinoma meeting Milan
criteria (awaiting liver transplantation) and those with HCV/HIV-1
co-infection. "It is our hope that Sovaldi will mark the beginning of a new
era in hepatitis C treatment. Gilead is proud to have played a role in
bringing about this important therapeutic advance and we would like to extend
our thanks to the many patients and physicians who partnered with us on
Sovaldi's clinical studies," said John C. Martin, PhD, Chairman and CEO,
Gilead. The Full Research Report on Gilead Sciences Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


St. Jude Medical Inc. Research Report

On December 9, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that
its Board of Directors has authorized and declared a Q4 2013 dividend in the
amount of $0.25 per common share. The Company also reported that this dividend
declaration brings the total dividend declared for the year to$1.00 per share.
The dividend is payable on January 31, 2014, to shareholders of record on
December 31, 2013. The Full Research Report on St. Jude Medical Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Cigna Corp. Research Report

On December 10, 2013, Cigna Corp. (Cigna) announced that it has achieved 100%
on the HRC's 2014 Corporate Equality Index (CEI) and has been recognized as
one of the "Best Places to Work for LGBT Equality" by the Human Rights
Campaign (HRC) Foundation. "The diversity of our employee base is one reason
Cigna is so accomplished at serving our customers. We respect and value our
differences because they are good for our communities and for our company,"
said John Murabito, Executive Vice President of Human Resources and Services.
"We're proud to provide an open and affirming workplace for all people."
According to the Company, Cigna and the Cigna Foundation support lesbian, gay,
bisexual and transgender (LBGT) non-profit charities such as The Hetrick
Martin Institute (HMI), Gay, Lesbian and Straight Education Network (GLSEN),
and several others. The Full Research Report on Cigna Corp. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


Pharmacyclics Inc. Research Report

On December 9, 2013, Pharmacyclics, Inc. (Pharmacyclics) announced the
publishing of results of a study evaluating ibrutinib in previously untreated
elderly patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) by The Lancet Oncology. The Company reported that the primary
endpoint of the study was safety, as assessed by the frequency and severity of
adverse events (AEs). Pharmacyclics informed that across all patients, the
estimated progression-free survival (PFS) and overall survival at 24 months
were 96.3% and 96.6%, respectively. "Older patients with CLL and SLL are at
particularly high risk, and the standard of care therapies for these patients
can often lead to significant and burdensome complications," said Susan
O'Brien, M.D., Department of Leukemia, Division of Cancer Medicine, The
University of Texas MD Anderson Cancer Center, who is also the lead author of
the study. "There is a need for new treatment options, and we are encouraged
by the high response rate and tolerability seen with ibrutinib as a first line
therapy." The Full Research Report on Pharmacyclics Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


LifePoint Hospitals Inc. Research Report

On December 2, 2013, LifePoint Hospitals Inc. (LifePoint) reported that the
Board of Directors ofBell Hospital (Bell) has finalized its agreement to be
acquired by LifePoint. LifePoint informed that under the terms of the
agreement, LifePoint will make $5 million in capital investments at Bell over
the next decade. "We are excited to welcome Bell Hospital to LifePoint," said
LifePoint Chairman and CEO William F. Carpenter III. "Providing quality
healthcare to patients is a top priority that Bell and LifePoint share. We
look forward to becoming part of the Ishpeming community and working with the
management team, physicians, staff and volunteers at Bell to explore ways to
help the hospital grow and prosper." According to LifePoint, the proceeds from
the acquisition transaction have eliminated Bell's debt, andthe Company
expects nearly $4 million in excess proceeds to be available from the
transaction. LifePoint further reported that Bell plans to use these funds to
support charitable activities in the community. The Full Research Report on
LifePoint Hospitals Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA


SOURCE Analysts' Corner

Contact: Contact: Joe Thomas, +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.